S. Sakaguchi, Regulatory T Cells, Cell, vol.101, issue.5, pp.455-458, 2000.
DOI : 10.1016/S0092-8674(00)80856-9

URL : https://hal.archives-ouvertes.fr/hal-01358192

E. M. Shevach, CD4 CD25 suppressor T cells: more questions than answers, Nat. Rev. Immunol, vol.2, pp.389-400, 2002.

M. C. Kullberg, D. Jankovic, P. L. Gorelick, P. Caspar, J. J. Letterio et al., ???induced Colitis, The Journal of Experimental Medicine, vol.158, issue.4, pp.505-515, 2002.
DOI : 10.1016/S1074-7613(00)80005-9

Y. Belkaid, C. A. Piccirillo, S. Mendez, E. M. Shevach, and D. L. Sacks, CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity, Nature, vol.223, issue.6915, pp.502-507, 2002.
DOI : 10.1038/nature01152

A. Van-maurik, M. Herber, K. J. Wood, and N. D. Jones, Cutting Edge: CD4+CD25+ Alloantigen-Specific Immunoregulatory Cells That Can Prevent CD8+ T Cell-Mediated Graft Rejection: Implications for Anti-CD154 Immunotherapy, The Journal of Immunology, vol.169, issue.10, pp.5401-5404, 2002.
DOI : 10.4049/jimmunol.169.10.5401

A. Trenado, F. Charlotte, S. Fisson, M. Yagello, D. Klatzmann et al., Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia, Journal of Clinical Investigation, vol.112, issue.11, pp.1688-1696, 2003.
DOI : 10.1172/JCI17702

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC281639/pdf

T. Sasada, M. Kimura, Y. Yoshida, M. Kanai, and A. Takabayashi, CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies, Cancer, vol.298, issue.5, pp.1089-1099, 2003.
DOI : 10.1002/cncr.11618

S. Onizuka, I. Tawara, J. Shimizu, S. Sakaguchi, T. Fujita et al., Tumor rejection by in vivo administration of anti- CD25 (interleukin-2 receptor alpha) monoclonal antibody, Cancer Res, vol.59, pp.3128-3133, 1999.

R. P. Sutmuller, L. M. Van-duivenvoorde, A. Van-elsas, T. N. Schumacher, M. E. Wildenberg et al., Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses, The Journal of Experimental Medicine, vol.60, issue.6, pp.823-832, 2001.
DOI : 10.1084/jem.190.5.705

J. Steitz, J. Bruck, J. Lenz, J. Knop, and T. Tuting, Depletion of CD25() CD4() T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8() T-cell-dependent immune defense of B16 melanoma, Cancer Res, vol.61, pp.8643-8646, 2001.

F. Ghiringhelli, N. Larmonier, E. Schmitt, A. Parcellier, D. Cathelin et al., CD4+CD25+ regulatory T???cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative, European Journal of Immunology, vol.34, issue.2, pp.336-344, 2004.
DOI : 10.1002/eji.200324181

M. J. Turk, J. A. Guevara-patino, G. A. Rizzuto, M. E. Engelhorn, and A. N. Houghton, Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells, The Journal of Experimental Medicine, vol.59, issue.6, pp.771-782, 2004.
DOI : 10.1038/nature01152

E. Y. Woo, H. Yeh, C. S. Chu, K. Schlienger, R. G. Carroll et al., Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation, The Journal of Immunology, vol.168, issue.9, pp.4272-4276, 2002.
DOI : 10.4049/jimmunol.168.9.4272

E. Y. Woo, C. S. Chu, T. J. Goletz, K. Schlienger, H. Yeh et al., Regulatory CD4()CD25() T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer, Cancer Res, vol.61, pp.4766-4772, 2001.

U. K. Liyanage, T. T. Moore, H. G. Joo, Y. Tanaka, V. Herrmann et al., Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma, The Journal of Immunology, vol.169, issue.5, pp.2756-2761, 2002.
DOI : 10.4049/jimmunol.169.5.2756

T. J. Curiel, G. Coukos, L. Zou, X. Alvarez, P. Cheng et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival, Nature Medicine, vol.165, issue.9, pp.942-949, 2004.
DOI : 10.1016/S0022-1759(01)00359-3

L. Ruggeri, M. Capanni, E. Urbani, K. Perruccio, W. D. Shlomchik et al., Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants, Science, vol.295, issue.5562, pp.2097-2100, 2002.
DOI : 10.1126/science.1068440

R. Castriconi, A. Dondero, R. Augugliaro, C. Cantoni, B. Carnemolla et al., Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis, Proc. Natl. Acad. Sci. USA, pp.12640-12645, 2004.
DOI : 10.1038/nri956

C. Borg, M. Terme, J. Taieb, C. Menard, C. Flament et al., Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell???dependent antitumor effects, Journal of Clinical Investigation, vol.114, issue.3, pp.379-388, 2004.
DOI : 10.1172/JCI21102DS1

A. Moretta, C. Bottino, M. C. Mingari, R. Biassoni, and L. Moretta, What is a natural killer cell?, Nature Immunology, vol.3, issue.1, pp.6-8, 2002.
DOI : 10.1038/ni0102-6

L. L. Lanier, On guard?activating NK cell receptors, Nature Immunology, vol.25, issue.1, pp.23-27, 2001.
DOI : 10.1038/83130

E. Vivier, J. A. Nunes, and F. Vely, Natural Killer Cell Signaling Pathways, Science, vol.306, issue.5701, pp.1517-1519, 2004.
DOI : 10.1126/science.1103478

URL : https://hal.archives-ouvertes.fr/hal-00080580

S. Bauer, V. Groh, J. Wu, A. Steinle, J. H. Phillips et al., Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA, Science, vol.285, issue.5428, pp.727-729, 1999.
DOI : 10.1126/science.285.5428.727

J. D. Wu, L. M. Higgins, A. Steinle, D. Cosman, K. Haugk et al., Prevalent expression of the immunostimulatory MHC class I chain???related molecule is counteracted by shedding in prostate cancer, Journal of Clinical Investigation, vol.114, issue.4, pp.560-568, 2004.
DOI : 10.1172/JCI200422206

S. A. Rosenberg, M. T. Lotze, J. C. Yang, P. M. Aebersold, W. M. Linehan et al., Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients, Annals of Surgery, vol.210, issue.4, pp.474-485, 1989.
DOI : 10.1097/00000658-198910000-00008

C. Baecher-allan, V. Viglietta, and D. A. Hafler, Human CD4+CD25+ regulatory T cells, Seminars in Immunology, vol.16, issue.2, pp.89-98, 2004.
DOI : 10.1016/j.smim.2003.12.005

K. Nakamura, A. Kitani, and W. Strober, Regulatory T Cells Is Mediated by Cell Surface???Bound Transforming Growth Factor ??, The Journal of Experimental Medicine, vol.157, issue.5, pp.629-644, 2001.
DOI : 10.1016/S0016-5085(00)70218-6

F. Annunziato, L. Cosmi, F. Liotta, E. Lazzeri, R. Manetti et al., Human Thymocytes, The Journal of Experimental Medicine, vol.57, issue.3, pp.379-387, 2002.
DOI : 10.4049/jimmunol.167.1.553

M. K. Levings, R. Sangregorio, C. Sartirana, A. L. Moschin, M. Battaglia et al., T Suppressor Cell Clones Produce Transforming Growth Factor ??, but not Interleukin 10, and Are Distinct from Type 1 T Regulatory Cells, The Journal of Experimental Medicine, vol.44, issue.10, pp.1335-1346, 2002.
DOI : 10.1084/jem.20020642

R. Castriconi, C. Cantoni, M. D. Chiesa, M. Vitale, E. Marcenaro et al., Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells, Proc. Natl. Acad. Sci. USA, pp.4120-4125, 2003.

J. D. Fontenot, M. A. Gavin, and A. Y. Rudensky, Foxp3 programs the development and function of CD4+CD25+ regulatory T cells, Nature Immunology, vol.4, issue.4, pp.330-336, 2003.
DOI : 10.1038/ni904

R. Glas, L. Franksson, C. Une, M. L. Eloranta, C. Ohlen et al., Recruitment and Activation of Natural Killer (Nk) Cells in Vivo Determined by the Target Cell Phenotype, The Journal of Experimental Medicine, vol.71, issue.1, pp.129-138, 2000.
DOI : 10.1111/j.1600-065X.1999.tb01292.x

M. Viguier, F. Lemaitre, O. Verola, M. S. Cho, G. Gorochov et al., Foxp3 Expressing CD4+CD25high Regulatory T Cells Are Overrepresented in Human Metastatic Melanoma Lymph Nodes and Inhibit the Function of Infiltrating T Cells, The Journal of Immunology, vol.173, issue.2, pp.1444-1453, 2004.
DOI : 10.4049/jimmunol.173.2.1444

J. Shimizu, S. Yamazaki, and S. Sakaguchi, Induction of tumor immunity by removing CD25CD4 T cells: a common basis between tumor immunity and autoimmunity, J. Immunol, vol.163, pp.5211-5218, 1999.

A. M. Wolf, D. Wolf, M. Steurer, G. Gastl, E. Gunsilius et al., Increase of regulatory T cells in the peripheral blood of cancer patients, Clin. Cancer Res, vol.9, pp.606-612, 2003.

P. Trzonkowski, E. Szmit, J. Mysliwska, A. Dobyszuk, and A. Mysliwski, CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction, Clinical Immunology, vol.112, issue.3, pp.258-267, 2004.
DOI : 10.1016/j.clim.2004.04.003

M. Ostroukhova, C. Seguin-devaux, T. B. Oriss, B. Dixon-mccarthy, L. Yang et al., Tolerance induced by inhaled antigen involves CD4+ T cells expressing membrane-bound TGF-?? and FOXP3, Journal of Clinical Investigation, vol.114, issue.1, pp.28-38, 2004.
DOI : 10.1172/JCI200420509

E. S. Doubrovina, M. M. Doubrovin, E. Vider, R. B. Sisson, R. J. O-'reilly et al., Evasion from NK Cell Immunity by MHC Class I Chain-Related Molecules Expressing Colon Adenocarcinoma, The Journal of Immunology, vol.171, issue.12, pp.6891-6899, 2003.
DOI : 10.4049/jimmunol.171.12.6891

A. M. Thornton and E. M. Shevach, Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production, The Journal of Experimental Medicine, vol.147, issue.2, pp.287-296, 1998.
DOI : 10.1111/j.1600-065X.1996.tb00897.x

A. M. Thornton and E. M. Shevach, Suppressor Effector Function of CD4+CD25+ Immunoregulatory T Cells Is Antigen Nonspecific, The Journal of Immunology, vol.164, issue.1, pp.183-190, 2000.
DOI : 10.4049/jimmunol.164.1.183

C. A. Piccirillo and E. M. Shevach, Cutting edge: control of CD8 T cell activation by CD4, 2001.

M. E. Brunkow, E. W. Jeffery, K. A. Hjerrild, B. Paeper, L. B. Clark et al., Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse, Nature Genetics, vol.27, issue.1, pp.68-73, 2001.
DOI : 10.1038/83784

M. J. Smyth, J. Swann, J. M. Kelly, E. Cretney, W. M. Yokoyama et al., NKG2D Recognition and Perforin Effector Function Mediate Effective Cytokine Immunotherapy of Cancer, The Journal of Experimental Medicine, vol.162, issue.10, pp.1325-1335, 2004.
DOI : 10.1038/ni857

A. Diefenbach, A. M. Jamieson, S. D. Liu, N. Shastri, and D. H. Raulet, Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages, Nature Immunology, vol.1, issue.2, pp.119-126, 2000.
DOI : 10.1038/77793

S. Hue, J. J. Mention, R. C. Monteiro, S. Zhang, C. Cellier et al., A Direct Role for NKG2D/MICA Interaction in Villous Atrophy during Celiac Disease, Immunity, vol.21, issue.3, pp.367-377, 2004.
DOI : 10.1016/j.immuni.2004.06.018

M. Terme, E. Tomasello, K. Maruyama, F. Crepineau, N. Chaput et al., IL-4 Confers NK Stimulatory Capacity to Murine Dendritic Cells: A Signaling Pathway Involving KARAP/DAP12-Triggering Receptor Expressed on Myeloid Cell 2 Molecules, The Journal of Immunology, vol.172, issue.10, pp.5957-5966, 2004.
DOI : 10.4049/jimmunol.172.10.5957